Published ahead of print on November 16, 2006, doi:10.1164/rccm.200510-1546OC
Am. J. Respir. Crit. Care Med., Volume 175, Number 4, February 2007, 323-329
A more recent version of this article appeared on February 15, 2007
Submitted on October 2, 2005
Accepted on November 16, 2006
Short Course Montelukast for Intermittent Asthma in Children: a Randomised Controlled Trial
Colin F Robertson1*, David Price2, Richard Henry3, Craig Mellis4, Nicholas Glasgow5, Dominic Fitzgerald4, Amanda J Lee2, Jane Turner6, and Melissa Sant6
1 Department of Respiratory Medicine, Royal Children's Hospital, Melbourne, Vic, Australia,
2 General Practice and Primary Care, University of Aberdeen, Aberdeen, United Kingdom,
3 Women's and Children's Health, University of NSW, Sydney, NSW, Australia,
4 Department of Respiratory Medicine, The Children's Hospital at Westmead, Sydney, NSW, Australia,
5 Medical School, Australian National University, Canberra, ACT, Australia,
6 Merck Sharp and Dohme (Australia) Pty. Ltd., Sydney, NSW, Australia
* To whom correspondence should be addressed. E-mail: colin.robertson{at}rch.org.au.
In children, intermittent asthma is the most common pattern and is responsible for the majority of exacerbations. Montelukast has a rapid onset of action and may be effective if used intermittently.
Objectives
To determine whether a short course of montelukast in children with intermittent asthma would modify the severity of an asthma episode.
Methods
Children, aged 2-14 years with intermittent asthma participated in this multi-center, randomized, double-blind, placebo-controlled clinical trial over a 12 month period. Treatment with montelukast or placebo was initiated by parents at the onset of URTI or asthma symptoms and continued for a minimum of 7 days or until symptoms had resolved for 48 hours.
Measurements and Main Results
220 children were randomised, 107 to montelukast and 113 to placebo. There were 681 treated episodes (345 montelukast, 336 placebo) provided by 202 patients. The montelukast group had 163 unscheduled healthcare resource utilisations for asthma compared to 228 in the placebo group (AR 0.65 (95% CI 0.47-0.89). There was a non-significant reduction in specialist attendances and hospitalisations, duration of episode, or -agonist and prednisolone use. Symptoms were reduced by 14% and nights awakened by 8.6% (p=0.043), days off from school or childcare by 37% and parent time off from work by 33% (p<0.0001 for both).
Conclusions
A short course of montelukast, introduced at the first signs of an asthma episode, results in a modest reduction in acute health care resource utilisation, symptoms, time off from school and parental time off from work in children with intermittent asthma.
Key words: asthma, pediatric, montelukast
This article has been cited by other articles:

|
 |

|
 |
 
M. M. del Giudice, A. Pezzulo, C. Capristo, E. Alterio, S. Caggiano, D. de Benedictis, and A. F. Capristo
Leukotriene modifiers in the treatment of asthma in children
Therapeutic Advances in Respiratory Disease,
October 1, 2009;
3(5):
245 - 251.
[Abstract]
[PDF]
|
 |
|

|
 |

|
 |
 
W. Lenney, A. L. Boner, L. Bont, A. Bush, K-H. Carlsen, E. Eber, B. Fauroux, M. Gotz, A. Greenough, J. Grigg, et al.
Medicines used in respiratory diseases only seen in children
Eur. Respir. J.,
September 1, 2009;
34(3):
531 - 551.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Bush
Update in Pediatric Lung Disease 2008
Am. J. Respir. Crit. Care Med.,
April 15, 2009;
179(8):
637 - 649.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Bush and P. L. P. Brand
From the authors
Eur. Respir. J.,
April 1, 2009;
33(4):
945 - 945.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
F. M. Ducharme, C. Lemire, F. J.D. Noya, G. M. Davis, N. Alos, H. Leblond, C. Savdie, J.-P. Collet, L. Khomenko, G. Rivard, et al.
Preemptive Use of High-Dose Fluticasone for Virus-Induced Wheezing in Young Children
N. Engl. J. Med.,
January 22, 2009;
360(4):
339 - 353.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
A. Bush
Practice Imperfect -- Treatment for Wheezing in Preschoolers
N. Engl. J. Med.,
January 22, 2009;
360(4):
409 - 410.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
I. Amirav, A. S. Luder, N. Kruger, Y. Borovitch, I. Babai, D. Miron, M. Zuker, G. Tal, and A. Mandelberg
A Double-Blind, Placebo-Controlled, Randomized Trial of Montelukast for Acute Bronchiolitis
Pediatrics,
December 1, 2008;
122(6):
e1249 - e1255.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
P. L. P. Brand, E. Baraldi, H. Bisgaard, A. L. Boner, J. A. Castro-Rodriguez, A. Custovic, J. de Blic, J. C. de Jongste, E. Eber, M. L. Everard, et al.
Definition, assessment and treatment of wheezing disorders in preschool children: an evidence-based approach
Eur. Respir. J.,
October 1, 2008;
32(4):
1096 - 1110.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
W. C. Moore
Update in Asthma 2007
Am. J. Respir. Crit. Care Med.,
May 15, 2008;
177(10):
1068 - 1073.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Cohen, J. Taitz, and A. Jaffe
Paediatric prescribing of asthma drugs in the UK: are we sticking to the guideline?
Arch. Dis. Child.,
October 1, 2007;
92(10):
847 - 849.
[Abstract]
[Full Text]
[PDF]
|
 |
|
Copyright © 2006 American Thoracic Society
|
|
|